This webinar is supported by Thermo Fisher.
Explore the significance of homologous recombination deficiency (HRD) in ovarian cancer. This fantastic webinar delves into methods and testing strategies of HRD, going beyond BRCA mutations, and discusses the potential clinical implications of HRD.
Philip Jermann, Clinical Sequencing Division, Thermo Fisher Scientific, Waltham, Massachusetts, USA, first presents a short overview of comprehensive genomic profiling and its role in clinical research of solid tumours. Nicola Normanno, Director, Translational Research, National Cancer Institute – Pascale Foundation, Italy, then presents a research study of the analytical validation of the Oncomine Comprehensive Assay Plus (Thermo Fisher) in his lab for the in-house assessment of HRD. He also presents a retrospective analysis on a cohort of ovarian cancer samples, and the correlation of the HRD status results with documented clinical outcomes*.
Nicola Normanno, Director, Translational Research, National Cancer Institute Pascale Foundation, Italy
Philip Jermann, Clinical Director, Medical Affairs, Clinical Sequencing Division, Thermo Fisher Scientific, Switzerland
